Intention de nommer des administrateurs
Cette annonce contient des informations privilégiées aux fins de l'article 7 du règlement (UE) n° 596/2014 qui fait partie du droit britannique en vertu de la loi de 2018 de l'Union européenne (retrait).
20 Mars 2024
Groupe ReNeuron plc
("ReNeuron", le "Réservation de groupe" ou la "Entreprise")
Decision of the Board of Directors to Appoint Administrators
Further to the announcement of 5 February 2024 in relation to the Company's current business development, financing discussions and working capital position (the "Annonce précédente"), ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that the board of directors (the "Conseil d'administration") has today resolved to appoint administrators to the Company with such appointment expected to take effect within the next business day.
As stated in the Previous Announcement, the Group has continued to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, has put staff at risk of redundancy and initiated discussions with its creditors. The Group has been actively engaged in discussions with its creditors in order to establish the solvency of the business, with a particular focus on finding solutions that would allow the Group to continue trading on a lower cost model. However, to date, certain of these discussions have not progressed sufficiently for the Group to establish the precise solvency status of the business and therefore due to this increased financial uncertainty the decision has been taken to appoint administrators. The discussions with potential investors, partners and creditors will remain open throughout the administration process and further updates will be made as and when appropriate.
Accordingly, the Board intends shortly to file the notice of appointment of Cork Gully LLP as administrators to the Company and a further announcement will be made in due course once the appointment has become effective. It is not known at present how much, if any, value will be returned to shareholders following the administration process.
The person responsible for arranging the release of this announcement on behalf of the Company is Iain Ross, Executive Chairman of the Company.
Enquêtes
ReNeuron | www.reneuron.com/investisseurs | ||
Iain Ross, président exécutif | Via Walbrook PR | ||
John Hawkins, directeur financier | |||
Allenby Capital Limited (conseiller désigné et Broker) | + 44 (0) 20 3328 5656 | ||
James Reeve/George Payne/Dan Dearden-Williams (Financement d'entreprise) | |||
Stefano Aquilino/Kelly Gardiner (Ventes et courtage d'entreprise) | |||
Walbrook PR (Relations avec les médias et les investisseurs) | +44 (0)20 7933 8780 ou [email protected] | ||
Paul Mc Manus / Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
À propos de ReNeuron
ReNeuron a développé une plate-forme exclusive d'administration de médicaments dérivée de cellules souches et basée sur des exosomes avec des capacités de ciblage cellulaire personnalisables pour l'administration de modalités de médicaments complexes.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX? platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
Les actions de ReNeuron sont négociées sur le marché AIM de Londres sous le symbole RENE.L. Pour plus d'informations visitez www.reneuron.com
Cette annonce contient des déclarations prospectives concernant la situation financière, les résultats d'exploitation et les réalisations/performances commerciales de ReNeuron et certains des plans et objectifs de la direction de ReNeuron à cet égard. Ces déclarations peuvent généralement, mais pas toujours, être identifiées par l'utilisation de mots tels que « devrait », « s'attend à », « estime », « croit » ou des expressions similaires.
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.